Haemonetics (HAE) is positioned for potential upside as the company has issued conservative fiscal 2027 guidance across its core segments Plasma, Hospital, and Blood Center, BofA Securities said in a note Friday.
Analysts highlighted strong plasma collection trends, with US volumes rising high single digits in fiscal Q4, indicating potential upside if momentum continues.
In the Hospital segment, the investment firm said vascular closure is improving with stronger commercial execution and blood management technologies are expected to remain a steady growth driver.
Some upside is also likely in the Blood Center segment, where management has guided for a mid-single-digit decline, BofA said.
Analysts cited potential catalysts, including Japan label expansion for vascular closure, the Japanese Red Cross plasma transition, possible tariff relief, and new products such as Vivasure's PerQseal Elite, with additional plasma innovation potentially supporting growth beyond 2027.
BofA upgraded Haemonetics stock to buy from neutral, and raised its price target to $80 from $72.
Shares of Haemonetics were up 2.7% in Friday trading.
Price: $63.64, Change: $+1.70, Percent Change: +2.74%